Skip to content
Markets News
Stocks1 min read

FDA Rejects Summit’s Ivonescimab Application, Shares Fall

Makkler Newsroom
November 16, 2026 · Based on reporting by MarketWatch, The Economic Times

The regulator cited a lack of statistically significant overall survival benefit, while investors await data from a separate first-line lung cancer trial.

Key takeaways

  • The FDA declined to approve Summit’s lung cancer drug ivonescimab.
  • The regulator cited a late-stage study’s failure to show a statistically significant overall survival benefit.
  • A separate global trial comparing ivonescimab with Keytruda is expected to report data later this year.

The US Food and Drug Administration declined to approve Summit Therapeutics’ experimental lung cancer drug ivonescimab. The agency cited a late-stage study that failed to show a statistically significant overall survival benefit.

Summit had sought approval for the drug with chemotherapy for previously treated patients with advanced non-squamous non-small cell lung cancer with EGFR mutations. The company later submitted longer follow-up results showing statistically significant overall survival, according to the report.

Summit shares were down 14% at $12.16 in morning trading, according to Reuters. As of 15:52 UTC, they traded at $12.38, down 12.51% from the previous close.

Investors are awaiting data later this year from a separate global late-stage trial comparing ivonescimab with Merck’s Keytruda as a first-line treatment.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.